CLL Information & Management Archives

January 30, 2023

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

On 1/27/23 [email protected] announced the Federal Drug Administration (FDA)’s accelerated approval of pirtobrutinib in adult patients with relapsed or refractory mantle cell lymphoma (MCL) following at least 2 lines of systemic therapy, including a BTK inhibitor.

January 30, 2023

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

As of 1/26/23, Evusheld (tixagevimab co-packaged with cilgavimab) is no longer available as Pre-Exposure Prophylaxis (PrEP) in the United States. That decision was made because as the virus continued to mutate, now over 90% of SARS-CoV-2 variants of concerns (VOC) circulating in the U.S. are no longer believed to

January 24, 2023

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

Dr. Sun was interviewed by Dr. Brian Koffman, a physician, CLL patient, and executive vice president and chief medical officer of CLL Society, at the ASH 2022 meeting in New Orleans. In the interview, she elaborates on the research results and recommendations on how patients can avoid cardiac issues

January 24, 2023

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

In this interview, our own Dr. Brian Koffman interviewed Dr. John Seymour, Director of the Department of Hematology at Peter MacCallum Cancer Centre & Royal Melbourne Hospital in Melbourne, Australia. They discussed the latest updates to the safety data from the ELEVATE R/R study, which was the first clinical

January 19, 2023

Zanubrutinib Approved in the U.S. for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)

With the FDA’s approval of zanubrutinib, CLL/SLL patients have another very strong choice to manage their disease.

January 13, 2023

Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Patients with CLL/SLL

\In this interview, Dr. Brian Koffman spoke with Dr. Shahzad Mustafa, Division Chief of Allergy, Immunology, and Rheumatology at Rochester Regional Health and Clinical Associate Professor of Medicine at the University of Rochester School of Medicine and Dentistry. They discussed immune deficiency (a.k.a. being immunocompromised) and what that means

January 6, 2023

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

Fixed-duration ibrutinib plus venetoclax provides an overall survival advantage and better sustained progression-free survival regardless of measurable residual disease (MRD) status compared with chlorambucil plus obinutuzumab as a first-line treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

January 6, 2023

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

In this ongoing trial, the triple combination therapy with acalabrutinib, venetoclax, and obinutuzumab is highly active and has thus far produced durable remissions as a frontline treatment in patients with TP53-aberrant chronic lymphocytic leukemia (CLL), which was generally well tolerated with a low 2.9% incidence of atrial fibrillation with

December 29, 2022

What Makes Being Diagnosed with CLL So Surprising

Dr. Koffman was interviewed by Prevention magazine to share some of his emotional experiences when he was diagnosed with chronic lymphocytic leukemia in 2005 and what he learned that helped him cope, primarily through the early part of his journey when he was asked to “Watch and Wait.” The

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

CLL Information & Management

FDA Approves Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

FDA Announces Evusheld is Not Currently Authorized for Emergency Use in the U.S.

ASH 2022: Dr. Clare Sun Explains Her Research on Sudden Death Among a Small Number of Chronic Lymphocytic Leukemia (CLL) Patients Using Ibrutinib

ASH 2022: Dr. John Seymour on the Adverse Event Burden of Acalabrutinib vs. Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL)

Zanubrutinib Approved in the U.S. for Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL)

Dr. Shahzad Mustafa on What it Means to be Immunocompromised for Patients with CLL/SLL

ASH 2022: Dr. Carsten Niemann with an Update on Fixed-Duration Ibrutinib Plus Venetoclax for Chronic Lymphocytic Leukemia (CLL) in the GLOW Study

ASH 2022: Dr. Christine Ryan on Triple Combination Acalabrutinib, Venetoclax, and Obinutuzumab for High-Risk Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

What Makes Being Diagnosed with CLL So Surprising

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT US

CONTACT